Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 27Triple Negative Breast Neoplasms 9Sarcoma 5Neoplasm Metastasis 4Liposarcoma 3Urinary Bladder Neoplasms 2Leiomyosarcoma 2Inflammatory Breast Neoplasms 2Carcinoma, Transitional Cell 2Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Refractory Solid Tumors 1Recurrence 1Metastatic HER2-positive Breast Cancer 1Inoperable Locally Advanced HER2-Negative Breast Cancer 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Hemangioendothelioma, Epithelioid 1HR+HER2- Breast Cancer 1HER2-low Breast Cancer 1Fludzoparib" and Anti-angiogenic 1Colorectal Neoplasms 1Brest Cancer 1Brain Neoplasms 1Advanced Breast Cancer 1

Interventions

pembrolizumab 3Paclitaxel 3Doxorubicin 3durvalumab 2Standard of Care 2Nivolumab 2Ipilimumab 2Ifosfamide 2zanidatamab 1veliparib 1tucatinib 1trilaciclib 1trebananib 1trastuzumab duocarmazine 1talazoparib 1spartalizumab 1sintilimab 1selinexor 1sarilumab 1regorafenib 1pexidartinib 1pertuzumab 1peginterferon alfa-2a 1pazopanib 1patritumab 1olaparib 1niraparib 1neratinib 1ganitumab 1eribulin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hemangiosarcoma × eribulin × 1 year × Clear all
NCT03331250 2025-12-23

Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)

Massachusetts General Hospital

Phase 2 Active not recruiting
13 enrolled 9 charts
Sarcoma

Hemangiosarcoma, Hemangioendothelioma, Epithelioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡